Abstract
Background: Primary plasma cell leukemia(pPCL) is a variant of multiple myeloma, accouting for 0.5-4% of myeloma. The median overall survival has been less than 1 year. The overall response rate of lenalidomide and dexamethasone(Rd) in newly diagnosed patients with pPCL has been presented to be 60%. We report a case of progressive pPCL with a favorable response to retreatment with Rd.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call